Advocacy

In 2015, the first biosimilar was approved in the United States. Since then, 31 have been approved by the FDA and 20 are on the U.S. market.
Biosimilars expand access to high-quality treatment options for clinicians and patients while reducing costs to families, caregivers,
public and private insurance plans, and the health care system.

Below is a database for the latest Biosimilars Forum statements on pressing policies, FDA resources on biosimilars for providers, patients, and industry professionals, along with recent news stories on developments within the biosimilars landscape

Biosimilars Forum Statements:

  • For the Biosimilars Forum’s statements regarding items of interest to the biosimilars community, please visit our News page.

Links to Biosimilars Information from the FDA:

Biosimilars Forum: State Biosimilars Substitution Compromise

CMS/Biosimilars Reimbursement 

Biosimilars in the News